Curis (CRIS) Releases Earnings Results, Reports EPS of $-0.09 EPS

Curis (CRIS) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.09 EPS for the quarter. Analysts had a consensus estimate of $-0.09. The company posted revenue of $1.70 million in the period, compared to analysts expectations of $2.05 million. The company’s revenue was down -19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.

Curis closed down -0.02 points or -1.15% at $1.72 with 1,77,928 shares getting traded on Tusday. Post opening the session at $1.75, the shares hit an intraday low of $1.7 and an intraday high of $1.76 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on May 27, 2016, Martyn D Greenacre (director) sold 15,000 shares at $1.69 per share price. According to the SEC, on May 27, 2016, Kenneth I Kaitin (director) sold 15,000 shares at $1.76 per share price. On Dec 30, 2015, Daniel R Passeri (director) sold 25,600 shares at $2.96 per share price, according to the Form-4 filing with the securities and exchange commission.

Curis Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company’s drug candidate CUDC-907 is an orally available small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis’ product pipeline also includes CUDC-427 an orally available small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma and human epidermal growth factor receptor 2 (HER 2-) estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company’s PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.


Leave a Reply

Curis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Curis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.